DOMINO-HD

Ne pas recruter

MISES À JOUR

Le recrutement pour cette étude d’observation financée par l’UE, qui vise à fournir de nouvelles informations sur le lien entre les facteurs liés au comportement et au mode de vie, d’une part, et le risque génétique et la progression de la HD, d’autre part, a finalement commencé en février, après les retards causés par la pandémie.

À PROPOS

SPONSOR

Cardiff University

PARTICIPANTS

300-450

DOMINO-HD est divisé en deux phases : la phase 1 étudie les méthodes permettant de mesurer de manière fiable les facteurs liés au mode de vie (activité physique, sommeil, alimentation) chez les personnes atteintes de la maladie de Huntington (MH), d’une manière qui perturbe le moins possible leur vie normale. La phase 2 utilisera les informations recueillies lors de la phase 1 pour mesurer ces facteurs de mode de vie chez les personnes atteintes de la maladie de Huntington pendant 12 mois. L’objectif principal de DOMINO-HD est d’étudier l’impact du sommeil, de la nutrition et de l’activité physique sur la progression de la maladie de Huntington, afin de développer de nouveaux moyens de soutenir et de gérer les aspects fondamentaux des patients atteints de HD. L’étude explorera également comment les technologies numériques, telles que les trackers de fitness portables, peuvent être utilisées pour soutenir les personnes atteintes de la maladie de Huntington.

Date estimée de fin de l’étude : Mars 2022

Ages éligibles
pour l'étude:

18 ans et plus


(Adulte, Adulte âgé)

Sexes éligibles
pour l'étude:

Tous

Accepte les volontaires en bonne santé:

Gène positif

Critères d'inclusion

Adultes (âgés de plus de 18 ans) ayant reçu un diagnostic de la maladie de Huntington confirmé par un test génétique, capables de marcher sans assistance et participant (actuellement ou nouvellement inscrits) à l’étude Enroll-HD.

Critères d'exclusion

  • Diagnostic de la maladie de Huntington à début juvénile (HD)
  • Antécédents d’affections neurologiques comorbides telles que la sclérose en plaques ou l’accident vasculaire cérébral.
  • Affections orthopédiques aiguës (dans un délai d’un mois) telles qu’une entorse ou une fracture de la cheville.
  • Conditions médicales graves telles qu’une maladie cardiaque instable ou progressive, un diabète non contrôlé, un dysfonctionnement grave du foie, des reins ou de la thyroïde, ou des conditions médicales similaires.
  • Tout état psychiatrique aigu ou instable
    Incapacité à tolérer le port prolongé du moniteur d’activité
  • Incapacité ou refus de donner un consentement éclairé écrit
    Pas d’accès à un smartphone
  • Refus de permettre à l’équipe de recherche d’installer sur leur smartphone des applications liées à l’étude

LOCATIONS

Questions générales

Cheney Drew
Tel: +44 (0)29 2068 7243
drewc5@cardiff.ac.uk

ALLEMAGNE

IRELANDE

TRIAL SITE: 
Universitätsklinikum Ulm

Address: Ulm, Baden-Württemberg, Germany, 89081

CONTACT
Nana Kovacevic
nana.kovacevic@uniklinik-ulm.de

Recruiting

TRIAL SITE:
University College Dublin, Ireland

Address: University College Dublin, Belfield, Dublin 4, Irland

CONTACT
Madeleine Lowery
Tel: +353 1 716 1911
madeleine.lowery@ucd.ie

Recruiting

POLOGNE

ESPAGNE

TRIAL SITE:
Institute of Psychiatry and Neurology, Warsaw

Address: Jana III Sobieskiego 9, Warszawa, 02-957 

CONTACT
Malgorzata Dusza-Rowinska
Tel: +48 694 904 208
m.dusza.rowinska@gmail.com

Recruiting

TRIAL SITE:
Hospital Universitario de Burgos

Address: Neurology Department, Avda Islas Baleares 3, Burgos, 09006

CONTACT
Carla Collazo
Tel: 947 256 533 ext 35380
ccollazo@ubu.es

Recruiting

SUISSE

ROYAUME-UNI

TRIAL SITE:
University Hospital Zurich

Address: Zürich, Switzerland, 08091

CONTACT
Hans Jung
hans.jung@usz.ch

Klavs Renerts
klavs.renerts@usz.ch

Recruiting

TRIAL SITE (Lead site):
Cardiff University

Address: Cardiff, United Kingdom, CF24 4HQ

CONTACT
Philippa Jones
Tel: +44 29206 87269
dominohd@cardiff.ac.uk

 

Recruiting

new FB feed (19)

dictionary:

SNP-single nucleotide polymorphisms

a single-letter spelling difference in a gene. SNPs, pronounced ‘snips’, are common and most don’t change the function of the gene.

 
new FB feed (19)

dictionary:

at risk

You do not know if you carry the genetic mutation for HD gene 

 
new FB feed (19)

dictionary:

TFC-total functional capacity

A standardized rating scale for function in HD, used to assess capacity to work, handle finances, perform domestic chores and self-care tasks.
Scores range from 0 to 13, with higher scores indicating better functional capacity. 

 
new FB feed (19)

dictionary:

Double-blinded

 means that neither the participant nor the clinical trial doctor can choose or know the group the participant is in until the trial is over. This approach helps to prevent bias.

new FB feed (19)

dictionary:

Open label

A trial in which the patient and doctor know what drug is being used. Open label trials are susceptible to bias through placebo effects.

new FB feed (19)

dictionary:

Gene therapy

a technique that aims to treat or prevent diseases by modifying a person’s genes. It involves introducing, removing, or changing genetic material (DNA or RNA) within a patient’s cells.

new FB feed (19)

dictionary:

UHDRS- Unified Huntington Disease Rating Scale

A standardized neurological examination that aims to provide a uniform assessment of the clinical features of HD

new FB feed (19)

dictionary:

CAG repeat

The stretch of DNA at the beginning of the HD gene, which contains the sequence CAG repeated many times, and is abnormally long in people who will develop HD

new FB feed (19)

dictionary:

Wild-type

the opposite of ‘mutant’. Wild-type huntingtin, for example, is the ‘normal’, ‘healthy’ protein

new FB feed (19)

dictionary:

Tolerabilty

How well a person can handle a treatment without having serious or uncomfortable side effects.

new FB feed (19)

dictionary:

Striatum

Part of the brain that  coordinates multiple aspects of cognition, including both motor and action planning, decision-making, motivation, reinforcement, and reward system.

new FB feed (19)

dictionary:

Randomized allocation

A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.

new FB feed (19)

dictionary:

Radioligand

a radioactive substance that binds to a specific target in the body, allowing visualization of that target’s distribution and activity

new FB feed (19)

dictionary:

Protein

Protein builds, maintains, and replaces the tissues in your body. The building blocks of life.

new FB feed (19)

dictionary:

Premanifest / Prodromal

Prior to onset or diagnosis of movement symptoms.

new FB feed (19)

dictionary:

Placebo

A placebo is a dummy medicine containing no active ingredients. The placebo effect is a psychological effect that causes people to feel better even if they’re taking a pill that doesn’t work.

new FB feed (19)

dictionary:

PK - Pharmacokinetics

The movement of drugs through the body

new FB feed (19)

dictionary:

PD - Pharmacodynamics

The body’s biological response to drugs

new FB feed (19)

dictionary:

PET scan

Positron emission tomography which produces detailed 3-dimensional images of the inside of the body.

new FB feed (19)

dictionary:

Neuron

Brain cells that store and transmit information

new FB feed (19)

dictionary:

MRI

Magentic resonance imaging: A technique using powerful magnetic fields to produce detailed images and visualizes the structure of organs, tissues, and bones 

new FB feed (19)

dictionary:

mHTT

Mutant huntingtin protein. The protein produced by the faulty HD gene.

new FB feed (19)

dictionary:

Manifest

after HD diagnosis, or when symptoms are already showing

new FB feed (19)

dictionary:

Longitudinal study

A study where each participant is looked at several times over a time period – unlike a cross-sectional study, where each participant is looked at only once

new FB feed (19)

dictionary:

HTT

one abbreviation for the gene that causes Huntington’s disease. The same gene is also called HD and IT-15

new FB feed (19)

dictionary:

fMRI

functional MRI:As with MRI, a technique using powerful magnetic fields  but focusing on brain function by measuring and mapping changes in blood flow, revealing which areas of the brain are active during specific tasks or cognitive processes

new FB feed (19)

dictionary:

CSF - cerebrospinal fluid

A clear fluid produced by the brain, which surrounds and supports the brain and spinal cord.

new FB feed (19)

dictionary:

Efficacy

A measure of whether a treatment works or not

new FB feed (19)

dictionary:

ASO(Antisense oligonucleotides)

A type of gene silencing treatment in which specially designed DNA molecules are used to switch off a gene

new FB feed (19)

dictionary:

Biomarker

a test of any kind – including blood tests, thinking tests and brain scans – that can measure or predict the progression of a disease like HD. Biomarkers may make clinical trials of new drugs quicker and more reliable

new FB feed (19)

dictionary:

BDNF

Brain-derived neurotrophic factor: a growth factor that may be able to protect neurons in HD.

new FB feed (19)

dictionary:

Allele

one of the two copies of a gene

new FB feed (19)

dictionary:

Plasma

Liquid component of the blood.

new FB feed (19)

dictionary:

Gene

The basic unit of heredity passed from parent to child. Genes are made up of sequences of DNA and are arranged, one after another, at specific locations on chromosomes in the nucleus of cells.

new FB feed (19)

dictionary:

Phase

Clinical trial phases are different stages of research that assess the safety and effectiveness of a new medical treatment or intervention in humans.

Each phase has a specific goal and involves a different number of participants. Generally, there are 4 phases (I-IV), with Phase I focusing on safety and dosage, Phase II on efficacy and side effects, Phase III on comparing the new treatment with standard treatments, and Phase IV on long-term safety monitoring.